Method for treating exacerbations in case of multiple sclerosis
FIELD: medicine, neurology.
SUBSTANCE: the method deals with detecting an interferon status followed by medicinal therapy. Moreover, additionally one should determine patient's body area, and at observed degree I of interferon system suppression it is necessary to prescribe "Antilympholin Kz" preparation as medicinal therapy intravenously by drops at course dosage being (0.5-0.6)g x S, where S - patient's body area, every other day, and thioctacide preparation at the dosage of 300-600 mg intravenously by drops daily at a 6-8-d-long course. In case of degrees II and III of interferon system suppression one should prescribe "Antilympholin Kz" at course dosage being 0.4-0.5 g/sq. m and 0.3 -.4 g/sq. m, as for thioctacide - it should be applied at the dosage of 600-900 mg and 900-1200 mg, correspondingly. The method enables to selectively affect the immune system efficiently due to combined prescription of an immunimodulator and a preparation that accelerates its introduction at suppressing the activity of proinflammatory cytokines that prolongs disease remission due to preventing the development of immunological disorders.
EFFECT: higher efficiency of therapy.
The invention relates to medicine, namely, neurology, and is intended for the treatment of acute exacerbations of multiple sclerosis. Using the proposed method it is possible to increase the efficiency of treatment of acute exacerbations of multiple sclerosis and reduce the risk of permanent disability.
Multiple sclerosis (PC) is a chronic progressive disease of the nervous system, characterized by the occurrence of multiple lesions in the Central nervous system. Studies conducted in our country and abroad, have identified a high proportion of PC. In the pathogenesis of multiple sclerosis are essential congenital disorders of immunity, increased permeability of the blood-brain barrier, the contact of immune cells with the basic myelin protein, antibody to myelin basic protein, the destruction of the myelin sheaths of nerve fibers in the Central and peripheral nervous system.
There is a method of treatment of acute exacerbations of multiple sclerosis cyclophosphamide. The drug was administered intravenously at a dose of 3 to 5 mg/kg (200 to 400 mg) per day for 10-14 days under the control of the blood (Neretin VA et al. "Immunosuppressive therapy of multiple sclerosis", Methodical recommendations, M., MONICA, 1992, p.14-15).
The disadvantages of this method are poor tolerability of the drug the patient, high risk of complications (hematological, infectious, and changes in the gastro-intestinal tract and liver). Cyclophosphamide is a derivative of mustard gas, refers to almyroudis compounds, the mechanism of action is to join their groups to the DNA, which leads to the destruction of molecules and cytotoxic effect. The drug acts on malagelada lymphocytes and causes inhibition of humoral effect and non-specific inflammatory reactions, thus not providing a selective action on the immune cell system and contributing to the progression of unwanted immunological disorders.
As a prototype of the selected method for the treatment of multiple sclerosis immunomodulatory drugs on the basis of the analysis of interferon status of the patient: pre-determine interferon status with the subsequent appointment of drug therapy. Determine the activity of interferon in the serum of the patient and in samples of whole blood incubated in medium RPMI - 1640 in the presence of standard inductors synthesis of interferons, by titration of the samples in cell culture and subsequent incubation with vesicular stomatitis virus (Application for invention of the Russian Federation No. 98105888, IPC G 01 N 33/68, publ. 2000).
The disadvantage of this method is the low efficiency is ity of treatment due to the lack of accounting for the activity of the autoimmune process, the lack of definition of boundaries of interferon status indicators for the purpose of different types of pathogenetic therapy of multiple sclerosis and as a consequence of the deepening of the autoimmune process in multiple sclerosis.
The problem posed by the authors, is to eliminate these drawbacks by eliminating unwanted immunological disorders by selective action on the immune cell system, based on the activity of the autoimmune process, clearly defining the boundaries of interferon status indicators, allowing you to assign adequate pathogenetic therapy depending on disease activity.
For this purpose, the method of treatment of an exacerbation of multiple sclerosis, including the determination of the interferon status with subsequent drug therapy, proposed to further define the area of the patient's body, as drug therapy to prescribe the drug "Antilepton KZ" intravenous drip in the course dose (0.5 to 0.6)g×S, where S is the area of the patient's body, through the day, and thioctacid in doses of 300-600 mg/drip daily at the rate of 6-8 days when I registered the degree of inhibition of the interferon system, II and III degree of inhibition of the interferon system similar to appoint "Antilepton KS" course dose of 0.4-0.5 g/m2and 0.3-0.4 g/m2and thioctacid in e is ze 600-900 900-1200 mg and mg, respectively.
Simultaneous application of Antilymphoma KS" and thioctacid allows you to accelerate the introduction of the drug "Antilepton short circuit and increase its effect by suppressing the activity protivovospolitelnyh cytokines.
In patients with active course of multiple sclerosis, continuing after a course of immunosuppressive therapy with glucocorticoids, pre investigate interferon status and subsequent prescribed drug therapy (drug "Antilepton KZ", contributing to increasing levels of anti-inflammatory cytokine α-interferon) with regard to the definition advanced area of the patient's body. In addition, to accelerate the introduction of the drug "Antilepton short circuit and increase its effect by inhibition of apoptosis and activity of proinflammatory cytokines at the same time prescribe the drug thioctacid. When I degree of inhibition of the interferon system (α-interferon 160-640 IU/ml and γ-interferon 32-128 u/ml) prescribe the drug "Antilepton PL/drip through the day in the amount of 3-4 injections at the dose rate of 0.5-0.6 g/m2and at the same time introducing/drip thioctacid in doses of 300-600 mg daily, with grade II (α-interferon 80-160 IU/ml and γ-interferon 16-32 units/ml)- drug "Antilepton short circuit" in the course dose of 0.4-0.5 g/m2and thioctacid dose of 600-900 mg, III degree (α-interferon <8 units/ml and γ -interferon <16 u/ml) - drug "Antilepton short circuit" in exchange dose of 0.3-0.4 g/m2and thioctacid dose of 900-1200 mg
The major difference of the proposed method from the prototype is the definition of the boundaries of the interferon status indicators taking into account the activity of the pathological process that allows you to choose the optimal treatment method as that of the original reduced sharply depressed, and in a satisfactory condition interferon system, to exclude a significant decrease of these indices in patients with PC, thus preventing further progression of immunological disorders.
Patient M., born in 1975, IB. 15295. Height 172 cm, weight 75 kg, body surface area 1.9 m2.
Diagnosed with multiple sclerosis, spinal form, the condition, the aggravation.
In the anamnesis of disease, 3 of deterioration, the present deterioration in the course of one month.
Neurological deficit at admission is on a scale FS=8 points, EDSS=3 points.
Immunological tests: the average level before treatment α-IFN - 240 u/ml, average γ-IFN - 48 u/ml (I degree of inhibition of interferon status), after treatment α-IFN - 480 u/ml, γ-IFN - 64 u/ml
Treatment: to calculate the dose of the drug "Antilepton KZ" pre-refinable by nomograms area of the skin of the patient: for a person with whom the OST 172 cm and weight 75 kg, it is S=1.9 m 2then taking into account the extent of inhibition of interferon system (patient she first degree) calculated dose rate of the drug at the rate of 0.6 g/m2(0,6×1,9=1,14 g). At the same time introduced daily/drip thioctacid when I degree of inhibition of interferon system in doses of 300-600 mg
Thus, we introduce a drug "Antilepton short circuit" in the course dose of 1.14 g/drip for 3 the introduction of a day and/drip thioctacid at a dose of 300 mg daily.
After treatment of neurological deficit scale FS=6 points, EDSS=2 points. For dynamic monitoring of the patient within 6 months of relapse of the disease was not observed.
Patient S., born in 1963, IB. 6654. Height 168 cm, weight 70 kg, body surface area 1.8 m2. Diagnosed with multiple sclerosis, spinal form, the condition, the aggravation.
In the history of the disease - 4 exacerbation of multiple sclerosis, when the last patient received hormone therapy with a positive effect, however, after the drug was the emergence of new symptoms.
Neurological deficit at admission is on a scale FS=7 points on the EDSS scale=2 points.
Immunological examination: medium α-IFN in the IRL before treatment - 120 IU/ml after treatment - 320 u/ml, average γ-IFN in the IRL before treatment 24 IU/ml after treatment 32 IU/ml
It was conducted by the prohibited treatment: to calculate the dose of the drug "Antilepton KZ" pre-specify normograms area of the skin of the patient: for a person with height is 168 cm and weight 70 kg it is 1.8 m 2then taking into account the extent of inhibition of interferon system (patient registered with II degree) calculate the exchange rate the dose rate of 0.5 g/m2(0,5×1,8=0.9 g). At the same time introduced daily/drip thioctacid with II degree of inhibition of interferon system in the dose of 600-900 mg
Thus, we introduce a drug "Antilepton KZ" 0.9 g on the course/drip N.3 and/drip thioctacid at a dose of 900 mg daily.
After treatment of neurological deficit scale FS=5 points, on a scale EDSS=1 point, i.e. positive neurological dynamics, kept for 1 year.
Patient J., born in 1972, IB. 21914. Height 170 cm, weight 73 kg, body surface area of 1.85 m2. Diagnosed with multiple sclerosis, spinal form, the secondary having a progressive course.
Medical history: has 2 exacerbation of the pathological process, after which the disease has been steadily progressing. The patient received prednisolone, against which there was a positive dynamics. However, if you cancel hormonal therapy neurological symptoms again increased.
Neurological deficit at admission is on a scale FS=15 points, EDSS=6 points. Immunological examination: medium α-IFN in the IRL before treatment - 80 IU/ml after treatment - 320 u/ml, average γ-IFN in the IRL before treatment 6 u/ml, after treatment - 24 IU/ml
Treatment: to calculate the dose of the drug "Antilepton KZ" pre-specify normograms area of the skin of the patient: for a person with a growth of 170 cm and a weight of 73 kg 1,85 m2then taking into account the extent of inhibition of interferon system (patient it III degree) calculated dose rate of the drug at the rate of 0.3 g/m2(0,3×1,85=0,555 g). At the same time introduced daily/drip thioctacid III-degree of inhibition of interferon system in the dose of 900-1200 mg
Thus was introduced the drug "Antilepton KZ" 0.56 g on the course/drip N.3 and/drip thioctacid at a dose of 1200 mg daily.
After treatment of neurological deficit scale FS=11 points, EDSS=5 points. Re-rate the above treatment was performed to the patient after 6 months due to symptoms of exacerbation of multiple sclerosis.
The present invention can effectively improve social rehabilitation of the patient, to improve the quality of life while reducing the economic costs associated with the disability of the patient and expenses for medications, increase the duration of remission.
Treatment of acute exacerbations of multiple sclerosis, including the determination of the interferon status with subsequent drug therapy, otlichalis the same time, what additionally is determined by the size of the patient's body, as the drug therapy prescribed drug "Antilepton KZ" intravenous drip in the course dose (0.5 to 0.6)g×S, where S is the area of the patient's body, through the day and thioctacid in doses of 300-600 mg intravenously daily for a course of 6-8 days when I registered the degree of inhibition of the interferon system, II and III degree of inhibition of the interferon system similar to appoint "Antilepton short circuit" in the course dose of 0.4-0.5 and 0.3-0.4 g/m2and thioctacid dose and 600-900 900-1200 mg, respectively.
FIELD: organic chemistry, biochemistry, medicine, pharmacy.
SUBSTANCE: invention relates to new substituted 1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]quinolines of the general formula (1)
that are effective inhibitors if caspase-3 that can be used for preparing medicinal agents and for experimental (in vitro, in vivo) investigation of apoptosis processes as "pharmacological tools". Also, invention proposes pharmaceutical composition and a method for their preparing and applying. In the general formula (1) radicals R1, R2, R3 and R8 represent independently of one another hydrogen atom, halogen atom, CF3, CN, inert substitute, optionally substituted hydroxyl group, optionally substituted carboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group; R4 represents hydrogen atom, halogen atom, inert substitute, optionally substituted amino-group, substituted hydroxyl group; R5 represents hydrogen atom, inert substitute, optionally substituted hydroxy-(C1-C5)-alkyl, optionally substituted amino-(C1-C7)-alkyl, optionally substituted amino-group, optionally substituted hydroxyl group; R6 and R7 represent independently of one another hydrogen atom, inert substitute, optionally substituted amino-(C1-C7)-alkyl, optionally substituted amino-group, optionally substituted hydroxyl group; or R6 and R7 in common with nitrogen atom to which they are bound represent optionally substituted and optionally additionally including heteroatom taken among group: oxygen, nitrogen or sulfur, 3-10-membered cycle; or R6 and R7 in common with nitrogen atom to which they are bound represent condensed heterocycle being optionally substituted and optionally additionally including heteroatom taken among group: oxygen, nitrogen or sulfur.
EFFECT: improved preparing method and treatment.
9 cl, 19 sch, 7 tbl, 25 ex
FIELD: organic chemistry, chemical technology, medicine, pharmacy.
SUBSTANCE: invention describes derivatives of benzodiazepine of the general formula (I)
and their pharmaceutically acceptable acid-additive salts wherein X means a ordinary bond or ethynediyl group; when X means ordinary bond then R1 means halogen atom, (lower)-alkyl, (lower)-alkylcarbonyl, (lower)-cycloalkyl, benzoyl, phenyl substituted optionally with halogen atom, hydroxyl, (lower)-alkyl, (lower)-alkoxy-group, halogen-(lower)-alkoxy-group or cyano-group; styryl, phenylethyl, naphthyl, diphenyl, benzofuranyl, or 5- or 6-membered heterocyclic ring representing thiophenyl, furanyl, pyridinyl, dihydropyridinyl, tetrahydropyridinyl which are optionally substituted; when X means ethynediyl group then R1 means hydrogen atom, (lower)-alkyl substituted optionally with oxo-group; (lower)-cycloalkyl substituted with hydroxyl; (lower)-cycloalkenyl substituted optionally with oxo-group; (lower)-alkenyl, optionally substituted phenyl; 5- or 6-membered heterocyclic ring representing thiophenyl, thiazolyl, pyridinyl, dihydropyridinyl, tetrahydropyridinyl or dihydropyranyl and substituted optionally; R3 means phenyl, pyridyl, thiophenyl or thiazolyl which are substituted optionally. These compounds can be used for treatment or prophylaxis of acute and/or chronic neurological diseases, such as psychosis, schizophrenia, Alzheimer's disease, disorder of cognitive ability and memory disorder. Also, invention describes a medicinal agent based on these compounds and a method for preparing compounds of the formula (I).
EFFECT: improved method for preparing, valuable medicinal properties of compounds.
10 cl, 1 tbl, 173 ex
FIELD: organic chemistry, heterocyclic compounds, medicine, pharmacy.
SUBSTANCE: invention relates to new heterocyclic compounds corresponding to general formulas: (I) , (II) , (Ia) and (Ib) wherein substitutes have values given in the description. Such compounds are reversible inhibitors of cathepsins S, K, F, L and B. Also, invention relates to a method for preparing these compounds, pharmaceutical composition eliciting inhibitory activity with respect to cysteine proteases and to a method for modulation of autoimmune diseases, treatment of Alzheimer's disease and osteoporosis.
EFFECT: improved method for preparing, valuable medicinal properties of compounds.
42 cl, 106 ex
FIELD: organic chemistry, pharmaceutical compositions.
SUBSTANCE: invention relates to substituted 3-oxo-1,2,3,4-tetrahydroxinoxalines of general formula 1 , wherein R1 represents substituted sulfanyl or substituted sulfonyl group, containing as substituent optionally substituted C1-C4-alkyl, optionally substituted C3-C8-cycloalkyl, aryl-(C1-C4)alkyl optionally substituted in aril or alkyl group, heterocyclyl-(C1-C4)alkyl optionally substituted in heterocycle or alkyl group; R2 and R3 independently represent hydrogen, halogen, CN, NO2, optionally substituted hydroxyl, optionally substituted amino group, optionally substituted carboxylic group, optionally substituted carbamoyl group, optionally substituted arylcarbonyl group or optionally substituted heterocyclylcarbonyl group; R4 and R5 independently represent hydrogen or inert substituent. Claimed compounds are high effective kaspase-3 inhibitors and are useful in production of pharmaceutical compositions for treatment of diseases associated with excess apoptosis activation, as well as for experimental investigations of apoptosis in vivo and in vitro. Also disclosed are pharmaceutical composition in form of tablets, capsules or injections in pharmaceutically acceptable package, as well as method for production thereof and therapy method.
EFFECT: pharmaceutical composition for apoptosis treatment and investigation.
6 cl, 3 dwg, 8 ex, 1 tbl
FIELD: pharmaceutical chemistry, medicine.
SUBSTANCE: in the suggested composition one should apply heptapeptide of Met-Glu-His-Phe-Pro-Gly-Pro sequence (heptapeptide A) for treating ischemic insult due to introducing 2 drops of compositions into each nasal canal 5-6 times daily for 10 d at disease of average severity degree, and in case of severe degree - per 3 drops of the present composition into each nasal canal 7 times daily for 10 d. The present innovation provides increased efficiency at decreased concentration of heptapeptide without any side effects.
EFFECT: higher efficiency of therapy.
2 cl, 6 dwg, 8 ex, 5 tbl
FIELD: organic chemistry, biochemistry, biology.
SUBSTANCE: invention relates to a pharmaceutical composition eliciting the inhibitory effect on activity of serine protease (caspase-3) in the form of tablet, capsule or injections placed into acceptable package, to a method for its preparing and a method for treatment of diseases associated with enhanced activation of apoptosis. The composition comprises compound 2,3-dihydro-1H-benzo[g]pteridine-4-one of the general formula (1) (1)
or its salt with pharmacologically acceptable acid as an active component taken in pharmaceutically effective amount wherein X means oxygen (O) or sulfur (S) atom; R1 and R2 represent independently of one another hydrogen atom, inert substitute taken among the group including low- or non-reactive and optionally substituted radical, such as (C1-C7)-alkyl, (C2-C7)-alkenyl, (C2-C7)-alkynyl, (C1-C7)-alkoxy-group, (C7-C12)-aralkyl, (C7-C12)-heterocyclylalkyl, (C7-C12)-alkaryl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkenyl, phenyl, aryl, heterocyclyl; optionally substituted hydroxy-(C1-C5)-alkyl group; R3, R4, R5 and R6 represent independently of one another hydrogen, halogen atom, -CF3, -CN, inert substitute taking among the group including low- or non-reactive and optionally substituted radical, optionally substituted hydroxyl group, optionally substituted hydroxy-(C1-C5)-alkyl group, optionally substituted amino-group, optionally substituted amino-(C1-C7)-alkyl group, optionally substituted carboxy-(C1-C7)-alkyl group, optionally substituted (C1-C6)-alkylcarboxy-(C1-C6)-alkyl group, optionally substituted carbamoyl group, optionally substituted (C1-C6)-alkylcarbamoyl group, optionally substituted sulfamoyl group. Also, invention relates to applying compounds of the formula (1) for preparing pharmaceutical composition and experimental study (in vitro and in vivo) processes associated with apoptosis.
EFFECT: improved preparing method, valuable medicinal and biochemical properties of composition.
7 cl, 1 dwg, 2 tbl, 5 ex
SUBSTANCE: one should apply glycosaminoglycanes at average molecular weight being 2400 D to prepare pharmaceutical composition for treating senile feeble-mindedness and neurological cerebral lesions induced due to sudden attack or trauma. The innovation suggested increases the number of medicinal preparations of necessary indication.
EFFECT: higher efficiency of application.
7 cl, 2 dwg, 8 tbl
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to nootropic, cerebroprotective medicinal agents as tablets. Tablet of a medicinal agent comprises thiotriazoline and piracetam as active components and accessory components used for formation of core and applying an envelope on it. Invention provides elevating rate and power of a medicinal agent effect on the brain blood supply, expanding spectrum of its pharmacological effect and excludes negative adverse effects.
EFFECT: improved and valuable medicinal properties of agent.
FIELD: organic chemistry, medicine.
SUBSTANCE: invention relates to new biologically active benzoxazine compounds and describes derivatives of benzoxazine of the following structure: wherein X1 and X2 are taken independently among hydrogen atom (H), -OR4, -CH2OR4; or X1 and X2 taken in common represent -O-CR
EFFECT: valuable medicinal properties of compounds.
107 cl, 2 dwg, 2 tbl, 10 ex
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to a group of new derivatives of 4,5-dihydro-1H-pyrazole of the general formula (I):
wherein R means phenyl, thienyl or pyridyl and these indicated groups can be substituted with (C1-C3)-alkoxy-group or halogen atom; R1 means phenyl that can be substituted with (C1-C3)-alkoxy-group or pyridyl group; R2 means hydrogen atom or hydroxy-group; Aa means one group among the following groups: (i) , (ii) , (iii) , (iv) or (v) ; R4 and R5 mean independently from one another hydrogen atom or (C1-C8)-branched or unbranched alkyl; or R4 means acetamido- or dimethylamino-group or 2,2,2-trifluoroethyl, or phenyl, or pyridyl under condition that R5 means hydrogen atom; R6 means hydrogen atom at (C1-C3)-unbranched alkyl; Bb means sulfonyl or carbonyl; R3 means benzyl, phenyl or pyridyl that can be substituted with 1, 2 or 3 substitutes Y that can be similar or different and taken among the group including (C1-C3)-alkyl or (C1-C3)-alkoxy-group, halogen atom, trifluoromethyl; or R3 means naphthyl, and its racemates, mixtures of diastereomers and individual stereoisomers and as well as E-isomers, Z-isomers and mixture of E/Z-compounds of the formula (I) wherein A has values (i) or (ii), and its salt. These compounds are power antagonists of Cannbis-1 (CB1) receptor and can be used for treatment of psychiatric and neurological diseases. Except for, invention relates to a pharmaceutical composition used for treatment of some diseases mediated by CB1-receptor, to a method for preparing this composition, a method for preparing representatives of compounds of the formula (I) wherein Aa means group of the formulae (i) or (ii), intermediate compounds used for preparing compounds of the formula (I) and to a method for treatment of some diseases mediated by CB1-receptor.
EFFECT: valuable medicinal properties of compounds.
16 cl, 9 ex
FIELD: medicine, immunology.
SUBSTANCE: method involves inhalation administration of combination of immunocorrecting agents wherein recombinant interleukin-2 is used or its combination with genetic engineering α2-interferon and with the complex immunoglobulin preparation in the daily doses for 5 days depending on age of patient. Before sanitation with an immunocorrecting agent the method involves assay of carrying type by anti-lysozyme activity of microorganisms (resident or transitory) and repeated examination after sanitation course is carried out. Carriers are subjected for additional sanitation with anti-bacterial preparations in change of carrying type from resident to transitory and with taking into account antibiotic-resistance property of the carrier strain. Method allows carrying out the effective sanitation and immune reablement of germ carriers due to recovery of the adequate natural resistance and complex of nonspecific factor of regional and systemic immunity.
EFFECT: improved and effective method for sanitation.
2 cl, 2 tbl, 5 ex
FIELD: medicine, immunology, pharmacy.
SUBSTANCE: invention relates to medicinal agents containing immunoglobulins and can be used for prophylaxis and treatment of bacterial and viral infections. Immunoglobulin preparation containing Ig G, Ig A and Ig M is subjected for sterilization by γ-irradiation with power of absorbed dose 3-6 kGr/h, total dose 12-30 kGr and design of different medicinal formulations on its base. Invention provides preparing the complex sterile immunoglobulin preparation comprising different classes of immunoglobulins with their retained biological activity.
EFFECT: improved method for preparing, valuable medicinal properties of preparation.
11 cl, 1 tbl, 8 ex
FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with inhibiting the growth of host's cerebral tumors. It deals with introducing therapeutically efficient quantity of integrin αv antagonists being cyclo(Arg-Gly-Asp-D-Phe-[N-Me]-Val). The innovation enables to considerably inhibit cerebral oncogenesis in vivo, moreover, despite antiangiogenesis, due to induction of direct lethality of tumor cells.
EFFECT: higher efficiency of inhibition.
9 dwg, 2 tbl
FIELD: medicinal biotechnology, immunology.
SUBSTANCE: invention relates to producing medicinal biological preparations. Invention relates to a method for enhancing specific activity of immunoglobulins of class G. Method involves freezing immunoglobulin G-containing fractions to temperature from -20°C to -196°C and subjected for gamma-irradiation in doses 5-50 kGr with power of absorbed dose 60-110 Gr/min. method provides elevating the specific activity of immunoglobulin G, increasing titer, avidity and reducing anti-complementary activity.
EFFECT: improved method for elevating activity of antibodies.
3 tbl, 3 dwg, 4 ex
FIELD: immunology, biotechnology, medicine.
SUBSTANCE: invention relates to antiidiotypical monoclonal antibody or fragment thereof for BSW17 antibody effecting on LgE Cε3-region bonding to high affinity LgE receptor. Amino acid sequence is as described in specification. antiidiotypical antibody is useful as pharmaceutical composition ingredient for LgE-mediated disease treatment. Invention make in possible to prevent allergic disorders and inflammations due to inhibiting interaction between LgE Cε3-region with high affinity receptor by claimed antibody.
EFFECT: new agent for allergic and inflammation disorder treatment.
7 cl, 32 dwg, 5 tbl, 10 ex
FIELD: veterinary science.
SUBSTANCE: animals should be introduced with antihistamine serum (AHS) subcutaneously at the dosage of 4.0-5.0 ml in combination with myxoferon at the quantity of 60-75 dosages and vitamin C at the dosage of 1.0-1.5 ml/animal, once daily, thrice at interval of 5-7 d. Application of AHS in combination with myxoferon and ascorbic acid provides active stimulation of immunological reactivity, increases total body resistance I animals and causes no toxic effects and allergic reactions.
EFFECT: higher efficiency of correction.
FIELD: medicine, pharmaceutics, pharmacology.
SUBSTANCE: one should apply mammalian anti-HBP-antibodies. The ways are being suggested to identify monoclonal antibody bound, at least, with one epitope upon native HBP (heparin-binding protein) and methods to detect whether a mammal produces HBR being bound with a monoclonal antibody and, also, the kits for the above-mentioned purpose. The present innovation provides the opportunity to apply the mentioned antibodies in preventing and treating disorders associated with bradykinin releasing.
EFFECT: higher efficiency of application.
25 cl, 11 dwg, 3 ex, 1 tbl
SUBSTANCE: the present innovation deals with cryoprotective ointment containing recombinant interferon-α2. The suggested cryoprotective ointment contains recombinant interferon-α2, glycerol, polyethylene glycol 300-6000, polyglucin, buffered 0.02%-Trilon B solution at pH of 5.5-7.0 and ointment foundation at a certain content of components per 1.0 g ointment. Additionally, cryoprotective ointment could contain glycine 3,7-bis(dimethylamino)phenothiazonium chloride, dry immunoglobulin preparation or dry immunoglobulin preparation for enteral application. Ointment foundation of cryoprotective ointment could contain water-free lanolin, Vaseline and Vaseline oil, at the following ratio of components: 2.5;3.5:1 - 6.5:0.5:1. The innovation provides maximal safety of recombinant interferon-α2 activity in cryoprotective ointment at multiple alteration of positive and negative environmental temperature and at keeping cryoprotective ointment under these conditions.
EFFECT: higher efficiency of application.
8 cl, 8 ex
FIELD: medicine and immunology, in particular treatment and prevention immunodeficiency conditions and diseases associated with bacterial or viral aggression.
SUBSTANCE: claimed method includes administration to a patient immunoglobulin drug (e.g., pharmaceutical composition containing 6-12 % of specific heterologous secreted immunoglobulin A, isolated from milk or foremilk of immunized ungulates). Administration is performed parenterally wherein single dose is at least 10 IU/kg of patient weight for treatment or at least 5 IU/kg for prophylaxis; or perorally in dose of 0.2-0.5 g and/or topically one-two times per day for 1-5 days. Method of present invention makes it possible to decrease dose of administrating immunoglobulin due to prolonged retention of its high titers in body fluids.
EFFECT: enlarged range of application and assortment of immunoglobulin drugs.
4 cl, 5 ex
FIELD: microbiology and immunology, in particular immunodiagnosis.
SUBSTANCE: atypical strain of melioidose Burkholderia pseudomallei-111-6-1 with altered phenotype defected with respect to synthesis of 8 antigen and acting as immunosuppressor is used as antigen for animal immunization. Immune serum is obtained after 2 immunization cycles of animal-producer with titer in gel immunodiffusion reaction not less than 1:128.
EFFECT: immune serum with increased specific activity.
2 tbl, 2 ex
FIELD: organic chemistry, medicine, pharmacology, biochemistry, pharmacy.
SUBSTANCE: invention proposes poly-(para-dihydroxy-para-phenylene)-thiosulfoacid sodium salt of the general formula:
wherein n = 2-6 as a substance regulating cell metabolism and eliciting anti-hypoxic properties. Also, invention proposes a pharmaceutical composition based on the indicated compound. Applying the compound provides the expressed anti-hypoxic effect. Invention can be used in cosmetology and food industry and relates to preparations regulating metabolism in separated cells and their consortium in biological tissues.
EFFECT: valuable biological and medicinal properties of compound.
4 cl, 10 tbl, 4 dwg, 6 ex